Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

Harold J. Burstein, MD, PhD
Published: Thursday, Jun 22, 2017



Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 


Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.

These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x